Combination Therapy Using Sodium-Glucose Co-
Transporter 2 Inhibitors and Glucagon-Like Peptide-1
Receptor Agonists for Treatment of Type 2 Diabetes
Volume 2 - Issue 5
Nasser Mikhail MD*
- Department of Medicine, Olive View-UCLA Medical Center, David-Geffen-UCLA School of Medicine, USA
Received: July 03, 2020 Published: August 05, 2020
Corresponding author: Nasser Mikhail MD, Chief, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center,
David-Geffen-UCLA School of Medicine, USA
DOI: 10.32474/ADO.2020.02.000149
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Background: The 2 drug classes of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2
(SGLT2) inhibitors are approved for type 2 diabetes, but their concomitant use was not sufficiently studied.Aim: To assess the safety
and efficacy of the combination of GLP-1RAs and SGLT2 inhibitors in type 2 diabetes.
Methods: Systematic review of English literature by search of electronic databases: Pub/MEDLINE from 2000 until July 2,
2020. Search terms included GLP-1 receptor agonists, SGLT2 inhibitors, combination therapy, add-on therapy, type 2 diabetes,
efficacy, safety. Randomized trials were included with more focus on double-blind, placebo-controlled trials. Post-hoc analysis and
consensus guidelines are also reviewed.
Results: One randomized trial evaluated the co-initiation of weekly exenatide plus dapagliflozin in patients with type 2 diabetes
uncontrolled on metformin. After 52 weeks, the reduction in glycated hemoglobin (HbA1c) levels with the combination therapy
was less than additive being 1.75%, 1.36%, and 1.23% with weekly exenatide + dapagliflozin, weekly exenatide + placebo and
dapagliflozin + placebo, respectively. Two randomized trials evaluated the sequential addition of GLP-1 RA to ongoing SGLT2
inhibitor therapy. Both trials reported greater HbA1c reduction averaging 0.8-1.4% compared with SGLT2 inhibitor + placebo. The
combination of GLP-1 RA + SGLT2 inhibitor caused significant weight loss of approximately 3.3 kg, which was slightly less than
additive, and 4.5 mmHg reduction in systolic blood pressure (SBP), which was more than additive. In general, the adverse effects
of combination therapy were expected, with no emergence of unusual adverse effects. The least tolerated combination included
semaglutide due to relatively high rates of gastrointestinal adverse events and mild hypoglycemia.
Conclusions: Combination therapy of GLP-1 RA plus SGLT2 inhibitor is overall effective and safe. Further studies are needed to
examine the effects of this combination on cardiovascular (CV), renal and mortality outcomes.
Keywords: Glucagon-like peptide-1 receptor agonist; SGLT-2 inhibitor; combination; efficacy; safety
Abstract|
Introduction|
Results from Randomized Double-Blind, Placebo-
Controlled Trials|
Simultaneous Addition of GLP-1 RAs and SGLT2
Inhibitors|
Sequential Addition of GLP-1 RAs to Ongoing SGLT2
Inhibitors|
Sequential Addition of SGLT2 Inhibitors to Ongoing
Therapy With GLP-1 RAs|
Effect on Weight|
Effect on Blood Pressure|
Effects on Other Intermediate Outcomes|
Effects on CV outcomes and mortality|
Safety of the Combination of GLP-1 RA Plus SGLT2
Inhibitor|
Conclusion|
References|